V.M. DELYAGIN

Federal Scientific and Clinical Centre of Pediatric Hematology, Oncology and Immunology named after Dmitry Rogachev, 1 Samori Maschel St., Moscow, Russian Federation, 117997 

Delyagin V.M. — D. Med. Sc., Professor, Head of the Department of Clinical Physiology, Head of the Department of Functional Diagnostics, tel. (495) 287-65-70 (48-09), e-mail: delyagin-doktor@yandex.ru

The drug-induced lung injuries develop in approximately 10% of cancer patients, in some cases leading to death. The real frequency of pneumotoxic reactions can be significantly larger. The drug pneumotoxicity is induced by a large number of anticancer drugs. Dose-dependent (usually sharp) and dose-independent reaction is possible. Acute reactions are characterized by the increased number of eosinophils in blood and in alveolar lavage fluid, eosinophilic infiltrates in lungs, pulmonary edema, respiratory distress syndrome, pleural effusion. The distant pneumotoxic reactions may occur after months or years after the drug use, such as interstitial pneumonia with the outcome to pulmonary fibrosis. In our opinion, the most sensitive are functional studies, revealing the restrictive changes and alveolar-capillary block.

Key words: lungs, side effects of antineoplastic drugs, children, oncology.

 

 

REFERENCES

1. Limper A. Chemotherapy induced lung disease. Clin. Chest. Med., 2004, 25, pp. 53-64.

2. Limper A. Drug induced lung disease: new developments. In: Braunwald E. (Ed.) Harrison’s online. New York, The MacGraw Hill Companies; 2000, available at: http://harrisons.accessmedicine.com. Accessed on 9 January 2004.

3. Limper A., Rosenow E. Drug-induced pulmonary disease. In: Murray J., Nadel J. (Ed.) Textbook of respiratory medicine. Philadelphia, W.B. Saunders Company, Inc., 2000. Pp. 1971-1994.

4. Scinner R., Kaplan R., Nathan P. The science of survivorship: moving from risk to risk reduction renal and pulmonary late effects of cancer therapy. Sem. Oncology, 2013, vol. 40, pp. 757-773.

5. Wolkowicz J., Sturgeon M., Rawji M., Chan C. Bleomycin-induced pulmonary function abnormalities. Chest, 1992, vol. 101, pp. 97-101.

6. Popova E.N. Drug-induced lung injury. Atmosfera, 2007, no. 2 (25), pp. 3-7 (in Russ.).

7. Review: Could cytosar cause increased permeability pulmonary edema?, available at: http://www.ehealthme.com/ds/cytosar-u/increased-permeability+pulmonary+edema

8. Santrach P., Askin F., Wells R., Azizkhan R., Merten D. Nodular form of bleomycin-related pulmonary injury in patients with osteogenic sarcoma. Cancer, 1989, vol. 64, pp. 806-811.

9. Cohen M., Austin J., Smith-Vaniz A., Lutzky J., Grimee M. Nodular bleomycin toxicity. Am. J. Clin. Pathol., 1989, vol. 92, pp. 101-104.

10. Myers L. Pathology of drug-induced lung disease. In: Katzenstein A., Askin F. (Eds.) Surgical pathology of non-neoplastic lung disease. 2nd edition. Philadelphia, W.B. Saunders. 1990. Pp. 97-127.

11. Jules-Elysee K., White D. Bleomycin-induced pulmonary toxicity. Clin. Chest. Med., 1990, vol. 11, pp. 1-20.

12. Ingrassia T., Ryu J., Trastek V, Rosenow E. Oxygen-exacerbated bleomycin pulmonary toxicity. Mayo Clin. Proc., 1991, vol. 66, pp. 173-178.

13. Goldiner P., Carlon G., Cvitkovic E., Schweizer O., Howland W. Factors influencing postoperative morbidity and mortality in patients treated with bleomycin. BMJ, 1978, vol. 1, pp. 1664-1667.

14. Kumar V., Abbas A., Aster J. The Lung. In: Robbins and Cotran Pathology Basis of Disease, Saunders, 2015. Pp. 669-726.

15. Mertens A., Yasni Y., Liu Y., Stovall M., Hutchinson R., Ginsberg J., Sklar C., Robinson L. Pulmonary complications in survivors of childhood and adolescent cancer. A report from the childhood cancer survivors study. Cancer, 2002, vol. 95 (11), pp. 2431-41.

16. Bedrossian C., Luna M., Conklin R. et al. Alveolar proteinosis as a consequence of immunosuppression. Hum. Pathol., 1980, vol. 11, pp. 527-535, available at: http://medsfacts.com/study-BUSULFAN-causing-ALVEOLAR%20PROTEINOSIS.php

17. Watanabe K., Sueishi K., Tanaka K., Nagata N., Hirose N., Shigematsu N., Miake S., Yoshida M. Pulmonary alveolar proteinosis and disseminated atypical mycobacteriosis in a patient with busulfan lung. Acta pathol. Jpn., 1990, vol. 40 (1), pp. 63-66.

18. Hallowell R., Horton M. Methotrexate interstitial lung disease in patients with rheumatoid arthritis: spontaneous and drug induced. Drugs, 2014, vol. 74 (4), pp. 443-450

19. Hasan F., Mark E. A 28-year-old man with increasing dyspnea, dry cough, and fever after chemotherapy for lymphoma. N Engl J Med, 1990, vol. 323, pp. 737-747.

20. Cannus P., Kudoh S., Ebina M. Interstitiale lung disease associated with drug therapy. BJC, 2004, vol. 91, (Supp. 2), S18-S23.

21. Helman Jr. DL., Byrd J., Ales N., Shor A. Fludarabine-related pulmonary toxicity: a distinct clinical entity in chronic lymphoproliferative syndromes. Chest, 2002, vol. 122 (3), pp. 785-790.

22. Garg S., Garg M., Basmaji N. Multiple pulmonary nodules: an unusual presentation of fludarabine pulmonary toxicity: case report and review of literature. Am. J. Hematology, 2002, vol. 70, pp. 241-245.

23. Meyer K., Decker C., Baughman R. Toxicity and monitoring of immunosupressive therapy used in systemic autoimmune diseases. Clinics Chest Med., 2011, vol. 31 (3), pp. 565-588.

24. Jehn J., Goldel N., Rienmauller R., Willmanns W. Noncardiogenic pulmonary edema complicating intermediate and high-dose Ara C treatment for relapsed acute leukemia. Med Oncol Tumor Pharmacother., 1988, vol. 5 (1), pp. 41-47.

25. Bhatla D., Gerbing R., Alonzo T., Conner H., Ross J., Meshinchi S., Zhai X., Zamzow T., Mehta P., Geoger H., Perentesis J., Davies S. Cytedine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia. Br. J. Haematol., 2009, vol. 144 (3), pp. 388-394.